soul trial oral semaglutide cardiovascular outcomes 2024 results nejm SOUL: Bests Usual Care in High-Risk Type 2 Diabetes Oral Semaglutide and Cardiovascular Outcomes

Description

Examining urine was a common diagnostic practice among physicians from the fourth millennium BCE

UK outlook for GLP-1 Diabetes Treatment Drugs Market Revenue from GLP-1 diabetes treatment drugs in the United Kingdom is projected to grow at a CAGR of 21.5% through 2035, supported by the country's healthcare system development, advanced diabetes care capabilities, and established expertise in pharmaceutical solutions

Lifestyle activities may also count as part of your workout routine, including walking the dog or taking a bike ride to work every day

Full agonism of these GPCRs through both G-protein and -arrestin signaling arms may be suboptimal, promoting undesirable off-target effects and receptor desensitization

Cardiovascular protective effects have been observed with both drug classes, reducing major adverse cardiovascular events in patients with T2DM and obesity and demonstrating symptomatic benefits in HFpEF